Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07207200 · ClinicalTrials.gov registry record · NA
Impact of Morning Light Therapy in IBD
A NA study of Inflammatory Bowel Disease, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07207200: Recruiting NA study of Inflammatory Bowel Disease, sponsored by Icahn School of Medicine at Mount Sinai.
NCT07207200 is a NA study of Inflammatory Bowel Disease that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30 participants, below the 403-participant average among 28 other Inflammatory Bowel Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07207200, a NA study of Inflammatory Bowel Disease, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The pilot study will focus on the effects of morning light therapy (MLT) in adult patients with ulcerative colitis (UC) who have evidence of poor sleep quality and active inflammation. The specific population is at risk for circadian rhythm sleep-wake disorders and has significant potential benefit from circadian realignment, which may lead to improved sleep quality and, ultimately, UC-related inflammatory activity. During an initial one-week lead-in period, participants will obtain baseline circadian-related labs, complete symptom-related surveys, and use a wearable device continuously to obtain baseline sleep-wake data. After the lead-in week, patients will undergo one hour of MLT while wearing wearable devices continuously and completing daily symptom surveys. At the end of four weeks of MLT, patients will obtain post-intervention circadian and inflammatory assessments in addition to completing the same symptom-related surveys.
Primary Outcome
C-reactive protein (CRP) is produced by the liver. The CRP test is a general test to check for inflammation in the body.
Conditions Studied
Interventions
- DEVICE Morning Light Therapy
Study Locations (1)
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-07-01 |
| Phase | NA |
What NCT07207200 shows while recruiting
NCT07207200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 403-participant average among 28 other Inflammatory Bowel Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Inflammatory Bowel Disease appearing as the primary indexed condition, and to 1 intervention - of which Morning Light Therapy is the first listed.
NCT07207200 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07207200 about?
NCT07207200 is a clinical study titled "Impact of Morning Light Therapy in IBD". The pilot study will focus on the effects of morning light therapy (MLT) in adult patients with ulcerative colitis (UC) who have evidence of poor sleep quality and active inflammation. The specific population is at risk for circadian rhythm sleep-wake disorders and has significant potential benefit ...
What is the current status of trial NCT07207200?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-03. Estimated completion is 2027-07-01.
What conditions does trial NCT07207200 study?
This clinical trial studies the following conditions: Inflammatory Bowel Disease.
What interventions are being tested in trial NCT07207200?
The interventions under investigation include: Morning Light Therapy (DEVICE).
Who is sponsoring clinical trial NCT07207200?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07207200 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07207200's enrollment target sits among peer trials
30 25th of 28 higher than 3 of 28 other Inflammatory Bowel Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammatory Bowel Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Mediterranean Diet in Inflammatory Bowel Disease
RECRUITING · NA
-
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
RECRUITING · NA
-
The Influence of a Fasting Mimicking Diet on Ulcerative Colitis
RECRUITING · NA
-
Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory Bowel Disease
RECRUITING · NA
-
Treatment of Depressed Adolescents With Physical Illness
COMPLETED · NA
-
Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia